VANCOUVER, British Columbia & QUEBEC CITY--(BUSINESS WIRE)--ImStar Therapeutics today announced the selection of IMS-088 as its lead drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company is preparing to initiate IND-enabling studies in the second half of 2014. IMS-088 is a novel, small-molecule drug that stems from the discovery of a new target for ALS by ImStar co-founder Dr. Jean-Pierre Julien termed TANA (i.e. TDP-43 Associated NF-?B Activation). IMS-088 is the first in a series of novel drugs derived from withaferin A, a natural compound isolated from the leaves of the winter cherry plant (Withania somnifera) that inhibits activation of a key inflammation pathway.
Help employers find you! Check out all the jobs and post your resume.